Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer

Yoshiro Fujiwara, Katsuyuki Kiura, Shinichi Toyooka, Nagio Takigawa, Masaki Tokumo, Katsuyuki Hotta, Motoi Aoe, Masahiro Tabata, Keitaro Matsuo, Hiroshi Date, Mitsune Tanimoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. Patients and methods: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. Results: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3%). The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78% versus 21%, P <0.001). Conclusion: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalLung Cancer
Volume52
Issue number1
DOIs
Publication statusPublished - Apr 2006

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Exons
Exanthema
Diarrhea
gefitinib
Liver
Interstitial Lung Diseases
Wounds and Injuries
Therapeutics
Neoplasms

Keywords

  • Adverse event
  • EGFR mutation
  • Gefitinib
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. / Fujiwara, Yoshiro; Kiura, Katsuyuki; Toyooka, Shinichi; Takigawa, Nagio; Tokumo, Masaki; Hotta, Katsuyuki; Aoe, Motoi; Tabata, Masahiro; Matsuo, Keitaro; Date, Hiroshi; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 52, No. 1, 04.2006, p. 99-103.

Research output: Contribution to journalArticle

@article{d7b82a15198a48d8ad193785a9dd3b71,
title = "Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer",
abstract = "Purpose: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. Patients and methods: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. Results: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3{\%}). The principal adverse event was skin rash (89{\%}), diarrhea (39{\%}), and liver injury (39{\%}). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78{\%} versus 21{\%}, P <0.001). Conclusion: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.",
keywords = "Adverse event, EGFR mutation, Gefitinib, Lung cancer",
author = "Yoshiro Fujiwara and Katsuyuki Kiura and Shinichi Toyooka and Nagio Takigawa and Masaki Tokumo and Katsuyuki Hotta and Motoi Aoe and Masahiro Tabata and Keitaro Matsuo and Hiroshi Date and Mitsune Tanimoto",
year = "2006",
month = "4",
doi = "10.1016/j.lungcan.2005.12.004",
language = "English",
volume = "52",
pages = "99--103",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer

AU - Fujiwara, Yoshiro

AU - Kiura, Katsuyuki

AU - Toyooka, Shinichi

AU - Takigawa, Nagio

AU - Tokumo, Masaki

AU - Hotta, Katsuyuki

AU - Aoe, Motoi

AU - Tabata, Masahiro

AU - Matsuo, Keitaro

AU - Date, Hiroshi

AU - Tanimoto, Mitsune

PY - 2006/4

Y1 - 2006/4

N2 - Purpose: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. Patients and methods: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. Results: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3%). The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78% versus 21%, P <0.001). Conclusion: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.

AB - Purpose: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. Patients and methods: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. Results: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3%). The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78% versus 21%, P <0.001). Conclusion: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.

KW - Adverse event

KW - EGFR mutation

KW - Gefitinib

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33644762763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644762763&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.12.004

DO - 10.1016/j.lungcan.2005.12.004

M3 - Article

VL - 52

SP - 99

EP - 103

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -